From Wikipedia, the free encyclopedia
Jump to: navigation, search
Clinical data
Trade names Tenelia
Legal status
Legal status
  • Approved in Japan
CAS Number 760937-92-6
PubChem (CID) 11949652
ChemSpider 10123963
Chemical and physical data
Formula C22H30N6OS
Molar mass 426.58 g/mol
3D model (Jmol) Interactive image

Teneligliptin (INN; trade name Tenelia) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".[1]


It was created by Mitsubishi Tanabe Pharma and launched in September 2012 by both Mitsubishi Tanabe Pharma and Daiichi Sankyo in Japan.[2]

Licensing and use[edit]


It is approved for use in Japan, Korea and India. [3]


Teneligliptin has unique J shaped or anchor locked domain structure because of which it has a potent inhibition of DPP 4 enzyme.

Teneligliptin significantly controls glycemic parameters[clarification needed] with safety. No dose adjustment is required in renally impaired patients.[4]


  1. ^ Kishimoto, M (2013). "Teneligliptin: A DPP-4 inhibitor for the treatment of type 2 diabetes". Diabetes, metabolic syndrome and obesity : targets and therapy. 6: 187–95. doi:10.2147/DMSO.S35682. PMC 3650886Freely accessible. PMID 23671395. 
  2. ^ http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006054.html
  3. ^ Joanne Bronson; Amelia Black; T. G. Murali Dhar; Bruce A. Ellsworth; J. Robert Merritt. "Teneligliptin (Antidiabetic), Chapter: To Market, To Market - 2012". Annual Reports in Medicinal Chemistry. 48: 523–524. doi:10.1016/b978-0-12-417150-3.00028-4. 
  4. ^ Biochemical and Biophysical Research Communications, 2013, 434(2), 191-196